AI-Driven Revolution In Drug Discovery
The global AI-driven drug discovery market, valued at $1.7–6.3B in 2024, is projected to grow to $8.5–16.5B by 2030–2034, led by oncology. AI reduces R&D costs by up to 70%, accelerates timelines by 1–2 years, and improves success rates. Breakthroughs include generative AI, foundation models, and au
Q1. Could you start by giving us a brief overview of your professional background, particularly focusing on your expertise in the industry?
Having spent over two decades at the intersection of pharmaceutical innovation and advanced laboratory technologies, my career has been fundamentally about transforming how we discover and develop medicines. As Vice President of Core Research Technologies at Seagen/Pfizer, I led the strategic implementation of scalable research capabilities that enabled next-generation therapeutic development, particularly in the complex arena of Antibody Drug Conjugates.
My journey began with hands-on laboratory automation work, progressing through roles where I pioneered Next Generation Reconfigurable Research Laboratory Automation at Zymergen and designed comprehensive technology footprints for Eli Lilly's Innovation Hub. This progression from bench science to executive technology leadership has given me a unique perspective on both the tactical challenges and strategic opportunities in pharmaceutical R&D transformation.
What sets my expertise apart is the combination of deep technical understanding of automated laboratory systems with executive-level insight into how these technologies drive business outcomes. I've managed the integration of high-throughput screening platforms, antibody discovery workflows, and chemical conjugation processes while navigating the organizational and regulatory complexities that determine success or failure in pharmaceutical technology adoption.
Currently, I…
Create an account to continue reading
Create AccountAlready have an account? Sign in
Need an expert in this space?
Talk to an Industry Expert
Knowledge Ridge connects decision-makers with carefully vetted subject matter experts for one-on-one calls, research sprints, and advisory engagements — across 11 sectors and 163 sub-industries globally.
Comments
No comments yet. Be the first to comment!